Immutep LimitedImmutep LimitedImmutep Limited

Immutep Limited

No trades
No trades

Compare with Immutep Limited


Market capitalization
‪53.04 M‬USD
−0.3699USD
‪−39.79 M‬USD
0.00USD
‪146.13 M‬
Beta (1Y)
4.51
Next report date
Report period
EPS estimate
Revenue estimate

Details


CEO
Marc Voigt
Headquarters
Sydney
Founded
1987
IPO date
Jun 23, 1988
ISIN
US45257L1089
CUSIP
45257L108
FIGI
BBG002WD6SY6
Identifiers
ISIN US45257L1089
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.